take a look at C-Topical Solution Generic Name: cocaine hydrochloride Dosage Form: topical solution Side Effects Dosage Professional Interactions Pregnancy More Breastfeeding Warnings User Reviews Support Group Q & A Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here. C-Topical TM (cocaine hydrochloride) Topical Solution CII Rx only NOT FOR INJECTION OR OPHTHALMIC USE. Slideshow Inherited Risk: The BRCA Gene Explained C-Topical Solution Description Each mL contains: Cocaine hydrochloride 40 mg or 100 mg As aqueous solution. The topical solution contains the following inactive ingredients: citric acid, sodium benzoate, D&C Yellow No. 10, FD&C Green No. 3, and purified water. NOTE (for Glass Bottle): External surface of unopened bottle may be sterilized by ethylene oxide only. Do not steam autoclave. Cocaine hydrochloride USP is a crystalline, granular, or powder substance having a saline, slightly bitter taste that numbs tongue and lips. Cocaine hydrochloride is a local anesthetic. C-Topical Solution - Clinical Pharmacology Cocaine blocks the initiation or conduction of the nerve impulse following local application, thereby effecting local anesthetic action. Cocaine is absorbed from all sites of application, including mucous membranes and the gastrointestinal mucosa. Cocaine is degraded by plasma esterses, with the half-life in the plasma being approximately one hour. Indications and Usage for C-Topical Solution C-Topical is indicated for the introduction of local (topical) anesthesia of accessible mucous membranes of the oral, laryngeal and nasal cavities. Contraindications Cocaine hydrochloride is contraindicated in patients with a known history of hypersensitivity to the drug or to the components of the topical solution. Warnings RESUSCITATIVE EQUIPMENT AND DRUGS SHOULD BE IMMEDIATELY AVAILABLE WHEN ANY LOCAL ANESTHETIC IS USED. Carcinogenesis, Mutagenesis Long-term studies to determine the carcinogenic and mutagenic potential of cocaine are not available. Pregnancy Teratogenic Effects-Pregnancy Category C: Animal reproduction studies have not been conducted with cocaine. It is also not known whether cocaine can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Cocaine should be given to a pregnant woman only if needed. Precautions The safety and effectiveness of C-Topical depends on proper dosage, correct technique, adequate precautions, and readiness for emergencies. Standard textbooks should be consulted for specific techniques and precautions for various anesthetic procedures. The lowest dosage that results in effective anesthesia should be used to avoid high plasma levels and serious adverse effects. Debilitated, elderly patients, acutely ill patients, and children should be given reduced doses commensurate with their age and physical status. C-Topical should be used with caution in patients with severely traumatized mucosa and sepsis in the region of the proposed application. Use with caution in persons with known drug sensitivities. Adverse Reactions Adverse reactions may be due to high plasma levels as a result of excessive and rapid absorption of the drug. Reactions are systemic in nature and involve the central nervous system and/or the cardiovascular system. A small number of reactions may result from hypersensitivity, idiosyncrasy or diminished tolerance on the part of the patient. CNS reactions are excitatory and/or depressant, and may be characterized by nervousness, restlessness and excitement. Tremors and eventually clonic-tonic convulsions may result. Emesis may occur. Central stimulation is followed by depression, with death resulting from respiratory failure. Small doses of cocaine slow the heart rate, but after moderate doses, the rate is increased due to central sympathetic stimulation. Cocaine is pyrogenic, augmenting heat production in stimulating muscular activity and causing vasoconstriction which decreases heat loss. Cocaine is known to interfere with the uptake of norepinephrine by adrenergic nerve terminals, producing sensitization to catecholamines, causing vasoconstriction and mydriasis. Cocaine causes sloughing of the corneal epithelium, causing clouding, pitting, and occasionally ulceration of the cornea. The drug is not meant for ophthalmic use. Overdosage The fatal dose of cocaine has been approximated at 1.2 g., although severe toxic effects have been reported from doses as low as 20 mg. Symptoms - The symptoms of cocaine poisoning are referable to the CNS, namely the patient becomes excited, restless, garrulous, anxious and confused. Enhanced reflexes, headache, rapid pulse, irregular respiration, chills, rise in body temperature, mydriasis, exophthalmos, nausea, vomiting and abdominal pain are noticed. In severe overdoses, delirium, Cheyne-Stokes respiration, convulsions, unconsciousness, and death from respiratory arrest result. Acute poisoning by cocaine is rapid in developing. Treatment - The specific treatment of acute cocaine poisoning is the intravenous administration of a short-acting barbiturate or diazepam. Artificial respiration may be necessary. It is important to limit absorption of the drug. If entrance of the drug into circulation can be checked, and respiratory exchange maintained, the prognosis is favorable since cocaine is eliminated fairly rapidly. C-Topical Solution Dosage and Administration The dosage varies and depends upon the area to be anesthetized, vascularity of the tissues, individual tolerance, and the technique of anesthesia. The lowest dosage needed to provide effective anesthesia should be administered. Dosages should be reduced for children and for elderly and debilitated patients. C-Topical can be administered by means of cotton applicators or packs, instilled into a cavity, or as a spray. How is C-Topical Solution Supplied 4% C-Topical TM (cocaine hydrochloride) Topical Solution, clear, blue-green solution. NDC 0527-1728-74: Unit-of-Use Glass Bottle filled to contain 4 mL, one 4 mL bottle per carton. NDC 0527-1728-73: Multi-Dose Bottle of 10 mL. 10% C-Topical TM (cocaine hydrochloride) Topical Solution, clear, blue-green solution. NDC 0527-1729-74: Unit-of-Use Glass Bottle filled to contain 4 mL, one 4 mL bottle per carton. NDC 0527-1729-73: Multi-Dose Bottle of 10 mL. DEA Order Form Required. Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature]. Avoid freezing. Keep out of reach of children. Revised 05/12, Revision 2 11-166 Manufactured By Cody Laboratories, Inc. Cody, WY 82414 For Lannett Company, Inc. Philadelphia, PA 19136 Made in the USA PRINCIPAL DISPLAY PANEL - 4 mL/4% label NDC 0527-1728-74 Unit of Use 4 mL Lannett Rx Only C-Topical 4% CII (cocaine hydrochloride topical solution) Each mL contains Cocaine HCl 40 mg NOT FOR INJECTION OR OPHTHALMIC USE PRINCIPAL DISPLAY PANEL - 4 mL/4% box NDC 0527-1728-74 Lannett Unit-of Use 4 mL C-Topical 4% CII (cocaine hydrochloride topical solution) Each mL contains: Cocaine Hydrochloride 40 mg Rx Only NOT FOR INJECTION OR OPHTHALMIC USE PRINCIPAL DISPLAY PANEL - 4 mL/10% label NDC 0527-1729-74 Unit of Use 4 mL Lannett Rx Only C-Topical 10% CII (cocaine hydrochloride topical solution) Each mL contains Cocaine HCl 100 mg NOT FOR INJECTION OR OPHTHALMIC USE PRINCIPAL DISPLAY PANEL - 4 mL/10% box NDC 0527-1729-74 Lannett Unit-of Use 4 mL C-Topical 10% CII (cocaine hydrochloride topical solution) Each mL contains: Cocaine Hydrochloride 100 mg Rx Only NOT FOR INJECTION OR OPHTHALMIC USE C-TOPICAL cocaine hydrochloride solution Product Information Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0527-1728 Route of Administration TOPICAL DEA Schedule CII Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength COCAINE HYDROCHLORIDE (COCAINE) COCAINE HYDROCHLORIDE 40 mg in 1 mL Inactive Ingredients Ingredient Name Strength CITRIC ACID MONOHYDRATE SODIUM BENZOATE D&C YELLOW NO. 10 FD&C GREEN NO. 3 WATER Product Characteristics Color BLUE (Clear, blue-green solution) Score Shape Size Flavor Imprint Code Contains Packaging # Item Code Package Description 1 NDC:0527-1728-74 4 mL in 1 BOTTLE, GLASS 2 NDC:0527-1728-73 10 mL in 1 BOTTLE Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date UNAPPROVED DRUG OTHER 12/01/2008 C-TOPICAL cocaine hydrochloride solution Product Information Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0527-1729 Route of Administration TOPICAL DEA Schedule CII Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength COCAINE HYDROCHLORIDE (COCAINE) COCAINE HYDROCHLORIDE 100 mg in 1 mL Inactive Ingredients Ingredient Name Strength CITRIC ACID MONOHYDRATE SODIUM BENZOATE D&C YELLOW NO. 10 FD&C GREEN NO. 3 WATER Product Characteristics Color BLUE (Clear, blue-green solution) Score Shape Size Flavor Imprint Code Contains Packaging # Item Code Package Description 1 NDC:0527-1729-74 4 mL in 1 BOTTLE, GLASS 2 NDC:0527-1729-73 10 mL in 1 BOTTLE Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date UNAPPROVED DRUG OTHER 12/01/2008 Labeler - Lannett Company, Inc. (002277481) Establishment Name Address ID/FEI Operations Cody Laboratories, Inc. 028153216 ANALYSIS(0527-1729, 0527-1728), LABEL(0527-1728, 0527-1729), MANUFACTURE(0527-1729, 0527-1728), PACK(0527-1729, 0527-1728) Establishment Name Address ID/FEI Operations Lannett Company, Inc. 829757603 ANALYSIS(0527-1728, 0527-1729) Revised: 05/2012 Lannett Company, Inc. Next Interactions Print this page Add to My Med List More about C-Topical Solution (cocaine topical) Side Effects During Pregnancy or Breastfeeding Dosage Information Drug Interactions Support Group 0 Reviews Add your own review/rating Professional resources Cocaine Hydrochloride Topical Solution (FDA)} FEATURED: CAR-T Cell Therapy Overview Mechanism of Action KTE-C19 Studies KTE-C19 Cancer Targets Adverse Events Manufacturing Drug Status Rx Availability Prescription only C Pregnancy Category Risk cannot be ruled out 2 CSA Schedule High potential for abuse WADA Class Anti-Doping Classification Manufacturer Lannett Company, Inc. Recently Approved Lonhala Magnair Lonhala Magnair (glycopyrrolate) is a long-acting muscarinic antagonist (LAMA) bronchodilator for... Ozempic Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) analog administered once-weekly for the... Ogivri Ogivri (trastuzumab-dkst) is a HER2 / neu receptor antagonist biosimilar to Herceptin indicated for... Sublocade Sublocade (buprenorphine) is a once-monthly injectable partial opioid agonist formulation for the... More C-Topical Solution Rating No Reviews - Be the first! No Reviews - Be the first! Not Rated - Be the first!} } on occasion
they carry C-Topical Solution needful
EmoticonEmoticon